Mesoblast Cash Flow Statement
NASDAQ: MESOHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
14.29+0.54 (+3.93%)
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Mesoblast free cash flow
In fiscal 2025, Mesoblast generated -$50.0 million of operating cash flow and spent $680,000 on capital expenditures. That left free cash flow of -$50.6 million, a free-cash-flow margin of -294.4% of revenue.
Summary generated from market data by MetaCap's automated system. Methodology
Mesoblast cash flow statement (annual)
| Fiscal year (USD) | FY 20252025-06-30 | FY 20242024-06-30 | FY 20232023-06-30 | FY 20222022-06-30 | FY 20212021-06-30 | FY 20202020-06-30 | FY 20192019-06-30 | FY 20182018-06-30 | FY 20172017-06-30 | FY 20162016-06-30 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | -102.14M | -87.96M | -81.89M | -91.35M | -98.81M | -77.94M | -89.80M | -35.29M | -76.81M | -4.13M |
| Net Income growth (YoY) | — | — | — | — | — | — | — | — | — | — |
| Depreciation & Amortization | 6.40M | 4.67M | 4.11M | 4.38M | 4.26M | 3.67M | 2.14M | 2.65M | 3.06M | 2.19M |
| Stock-Based Compensation | 22.09M | 5.87M | 3.65M | 5.54M | 12.51M | 7.52M | 4.37M | 6.20M | 5.28M | 3.39M |
| Operating Cash Flow | -49.95M | -48.46M | -63.27M | -65.78M | -100.75M | -50.42M | -57.79M | -75.01M | -95.47M | -88.00M |
| Capital Expenditures | -680.00K | -271.00K | -264.00K | — | — | — | — | — | — | — |
| Investing Cash Flow | 120.00K | -97.00K | -194.00K | -232.00K | -1.65M | -3.27M | -1.00M | -1.15M | 142.00K | -1.73M |
| Debt Issued | — | 0 | 0 | 51.92M | 0 | 512.00K | 43.57M | 31.70M | — | — |
| Debt Repaid | -7.82M | -10.00M | 0 | -55.46M | 0 | -512.00K | — | — | — | — |
| Financing Cash Flow | 147.34M | 40.25M | 74.50M | -9.87M | 108.53M | 131.10M | 71.61M | 68.61M | 60.01M | 62.07M |
| Free Cash Flow | -50.63M | -48.73M | -63.53M | -65.78M | -100.75M | -50.42M | -57.79M | -75.01M | -95.47M | -88.00M |
This table shows 10 annual periods of Mesoblast's cash flow statement, from FY 2025 back to FY 2016, across 10 line items including net income, depreciation & amortization, stock-based compensation. Values in USD; B = billions, M = millions. Fiscal periods follow MESO's reporting calendar. What is a cash flow statement?